In conclusion, TMZ can be used as a reasonable therapy for the patients suffering from BMs due to NSCLC, especially in patients having no actionable oncogenic driver or resistance to EGFR-TKIs/ALK-TKIs. The gene discussed is ALK; the disease is non-small cell lung carcinoma.